These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31754584)

  • 1. Treatments for Primary Immune Thrombocytopenia: A Review.
    Samson M; Fraser W; Lebowitz D
    Cureus; 2019 Oct; 11(10):e5849. PubMed ID: 31754584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of immune thrombocytopenic purpura in children : current concepts.
    Shad AT; Gonzalez CE; Sandler SG
    Paediatr Drugs; 2005; 7(5):325-36. PubMed ID: 16220997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune thrombocytopenic purpura - current management practices.
    Sandler SG; Tutuncuoglu SO
    Expert Opin Pharmacother; 2004 Dec; 5(12):2515-27. PubMed ID: 15571469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
    Rodeghiero F
    Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
    Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
    Lv Y; Shi H; Liu H; Zhou L
    Front Immunol; 2022; 13():953716. PubMed ID: 36003388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama.
    Watts RG
    Clin Pediatr (Phila); 2004 Oct; 43(8):691-702. PubMed ID: 15494875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary management of primary immune thrombocytopenia in adults.
    Lakshmanan S; Cuker A
    J Thromb Haemost; 2012 Oct; 10(10):1988-98. PubMed ID: 22863415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
    Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura.
    Pasa S; Altintas A; Cil T; Danis R; Ayyildiz O
    J Thromb Thrombolysis; 2009 Apr; 27(3):329-33. PubMed ID: 18311541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
    Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
    BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of immune thrombocytopenic purpura in children: potential role of novel agents.
    Bredlau AL; Semple JW; Segel GB
    Paediatr Drugs; 2011 Aug; 13(4):213-23. PubMed ID: 21692546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO; Patekar MB; Milunović V
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acute immune thrombocytopenic purpura.
    Tarantino MD; Goldsmith G
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):28-35. PubMed ID: 9523747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura.
    Kojouri K; George JN
    Int J Hematol; 2005 Feb; 81(2):119-25. PubMed ID: 15765779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R; Pagano A; Stipa E; Amadori S
    Blood; 2001 Aug; 98(4):952-7. PubMed ID: 11493438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated guidelines for immune thrombocytopenic purpura: Expanded management options.
    DeSouza S; Angelini D
    Cleve Clin J Med; 2021 Dec; 88(12):664-668. PubMed ID: 34857604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.